de novo development of the prostate tumor, and is considered as a key factor required for HH pathway- driven tumorigenesis.38 We therefore examined whether NVP-LDE-225 regulates the expression of Bmi-1 in prostate CSCs by immunohistochemistry and western blot analysis (Figures 5a and b). As...
(b) Protein expression of Nanog, Oct-4, c-Myc and Sox-2. Prostate CSCs were treated with NVP-LDE-225 for 48 h, and the expression of Nanog, Oct-4, c-Myc and Sox-2 was determined by the western blot analysis. (c) Immunohistochemical examination of Nanog, Oct-4, c-Myc and Sox...
Unlike arsenicin A, arsenicin B proved to be quite reactive in the mass spectrometric chamber. In fact, during the acquisition of a set of spectra, a peak at m/z 422 (ca. 5% intensity with respect to the molecular ion) arose, while the intensity of the signal at m/z 360 peak, ...